IN2014DN07410A - - Google Patents
Info
- Publication number
- IN2014DN07410A IN2014DN07410A IN7410DEN2014A IN2014DN07410A IN 2014DN07410 A IN2014DN07410 A IN 2014DN07410A IN 7410DEN2014 A IN7410DEN2014 A IN 7410DEN2014A IN 2014DN07410 A IN2014DN07410 A IN 2014DN07410A
- Authority
- IN
- India
- Prior art keywords
- pharmaceutically acceptable
- inhibitor
- prodrug
- relates
- pharmaceutical combination
- Prior art date
Links
- 239000013066 combination product Substances 0.000 abstract 1
- 229940127555 combination product Drugs 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261619502P | 2012-04-03 | 2012-04-03 | |
| PCT/US2013/034759 WO2013151913A1 (en) | 2012-04-03 | 2013-04-01 | Tyrosine kinase inhibitor combinations and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN07410A true IN2014DN07410A (th) | 2015-04-24 |
Family
ID=48184451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN7410DEN2014 IN2014DN07410A (th) | 2012-04-03 | 2013-04-01 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150051210A1 (th) |
| EP (1) | EP2833917A1 (th) |
| JP (1) | JP2015512447A (th) |
| KR (1) | KR20140146086A (th) |
| CN (1) | CN104244982A (th) |
| AU (1) | AU2013243737B2 (th) |
| CA (1) | CA2866321A1 (th) |
| IN (1) | IN2014DN07410A (th) |
| MX (1) | MX2014011987A (th) |
| RU (1) | RU2014143213A (th) |
| WO (1) | WO2013151913A1 (th) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA39784B1 (fr) | 2014-03-26 | 2021-03-31 | Astex Therapeutics Ltd | Combinaisons des inhibiteurs du fgfr et du cmet destinées au traitement du cancer |
| AU2015294889B2 (en) * | 2014-07-31 | 2018-03-15 | Novartis Ag | Combination therapy |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| DE102005038537A1 (de) | 2005-08-16 | 2007-02-22 | Merck Patent Gmbh | 1-Acyldihydropyrazolderivate |
| NZ568807A (en) | 2005-12-21 | 2011-05-27 | Janssen Pharmaceutica Nv | Triazolopyridazines as tyrosine kinase modulators |
| NL2000613C2 (nl) | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
| PE20121506A1 (es) | 2006-07-14 | 2012-11-26 | Amgen Inc | Compuestos triazolopiridinas como inhibidores de c-met |
| EP2084162B1 (en) | 2006-10-23 | 2012-09-12 | SGX Pharmaceuticals, Inc. | Bicyclic triazoles as protein kinase modulators |
| SI3034075T1 (sl) * | 2006-11-22 | 2018-12-31 | Incyte Holdings Corporation | Imidazotriazini in imidazopirimidini kot inhibitorji kinaze |
| JP4994044B2 (ja) * | 2007-01-05 | 2012-08-08 | シェブロンジャパン株式会社 | 潤滑油組成物 |
| AU2008239594B2 (en) * | 2007-04-13 | 2013-10-24 | Beth Israel Deaconess Medical Center | Methods for treating cancer resistant to ErbB therapeutics |
| JP5539963B2 (ja) * | 2008-04-29 | 2014-07-02 | ノバルティス アーゲー | 線維芽細胞増殖因子受容体のキナーゼ活性のモジュレーションをモニタリングする方法、および該方法の使用 |
| WO2009140549A1 (en) * | 2008-05-14 | 2009-11-19 | Amgen Inc. | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
| CA2770873A1 (en) * | 2009-08-12 | 2011-02-17 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
| WO2012044577A1 (en) * | 2010-09-27 | 2012-04-05 | Exelixis, Inc. | Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases |
-
2013
- 2013-04-01 RU RU2014143213A patent/RU2014143213A/ru not_active Application Discontinuation
- 2013-04-01 CN CN201380018928.6A patent/CN104244982A/zh active Pending
- 2013-04-01 US US14/388,251 patent/US20150051210A1/en not_active Abandoned
- 2013-04-01 CA CA2866321A patent/CA2866321A1/en not_active Abandoned
- 2013-04-01 IN IN7410DEN2014 patent/IN2014DN07410A/en unknown
- 2013-04-01 KR KR1020147027542A patent/KR20140146086A/ko not_active Withdrawn
- 2013-04-01 MX MX2014011987A patent/MX2014011987A/es unknown
- 2013-04-01 JP JP2015504647A patent/JP2015512447A/ja active Pending
- 2013-04-01 EP EP13718671.4A patent/EP2833917A1/en not_active Withdrawn
- 2013-04-01 AU AU2013243737A patent/AU2013243737B2/en not_active Ceased
- 2013-04-01 WO PCT/US2013/034759 patent/WO2013151913A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| RU2014143213A (ru) | 2016-05-27 |
| MX2014011987A (es) | 2014-11-10 |
| AU2013243737B2 (en) | 2016-06-30 |
| JP2015512447A (ja) | 2015-04-27 |
| AU2013243737A1 (en) | 2014-09-25 |
| CN104244982A (zh) | 2014-12-24 |
| EP2833917A1 (en) | 2015-02-11 |
| KR20140146086A (ko) | 2014-12-24 |
| CA2866321A1 (en) | 2013-10-10 |
| US20150051210A1 (en) | 2015-02-19 |
| WO2013151913A1 (en) | 2013-10-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN00598A (th) | ||
| IN2014DN10670A (th) | ||
| MX2015002040A (es) | Baricitinib deuterado. | |
| PH12014501653A1 (en) | Metalloenzyme inhibitor compounds | |
| MA39749A (fr) | Dérivés de pipéridine-dione | |
| MX355728B (es) | Inhibidores de cinasas. | |
| JO3383B1 (ar) | مثبطات cdc7 | |
| HK1209277A1 (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors 124--6- | |
| EP3019166A4 (en) | A pharmaceutical combination for the treatment of melanoma | |
| MX366983B (es) | Derivados de 1,5-naftiridina e inhibidores de cinasa de cremallallera de leucina embrionica materna que los contienen. | |
| IN2014DN07996A (th) | ||
| IN2014DN11078A (th) | ||
| MX2015008829A (es) | Momelotinib deuterado. | |
| IN2014DN06738A (th) | ||
| MX2014015345A (es) | Inhibidores piranopiridona de tanquirasa. | |
| EP3192511A4 (en) | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor | |
| UA115072C2 (uk) | Похідні гідантоїну | |
| MY165088A (en) | Pharmaceutical compositions comprising alisporivir | |
| NZ717192A (en) | Anti-inflammatory tripeptides | |
| IN2014DN07410A (th) | ||
| PH12016500809B1 (en) | Glucopyranosyl - substituted indole-urea derivatives and their use as sglt inhibitors | |
| EP3166405A4 (en) | 3'-substituted-abscisic acid derivatives | |
| MX2015012610A (es) | Pacritinib deuterizado. | |
| EP3069326A4 (en) | Modular product vending system | |
| EP3016535A4 (en) | Modular impact protection system for athletic wear |